Intra-Cellular Therapies (ITCI) Tops Q4 EPS by 13c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($0.64), $0.13 better than the analyst estimate of ($0.77). Revenue for the quarter came in at $97.9 thousand, versus $30.66 thousand reported last year.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Shoe Station Group Inc. (SHOE) Tops Q2 EPS by 11c ; Offers Guidance
• Lightpath Technologies (LPTH) Misses Q4 EPS by 5c